메뉴 건너뛰기




Volumn 28, Issue 112, 2010, Pages

Effect of pioglitazone on proteinuria in non-diabetic renal patients: A self-control clinical trial

Author keywords

Hypoglycemic agent; Non diabetic renal disease; Pioglitazone; Proteinuria

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; PIOGLITAZONE;

EID: 78650644635     PISSN: 10277595     EISSN: 1735854X     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (1)

References (15)
  • 2
    • 38149021580 scopus 로고    scopus 로고
    • Antiproteinuric and antiinflammatory effects of thiazolidinedione
    • Szeto CC, Li PK. Antiproteinuric and antiinflammatory effects of thiazolidinedione. Nephrology (Carlton) 2008;13(1):53-7.
    • (2008) Nephrology (Carlton) , vol.13 , Issue.1 , pp. 53-57
    • Szeto, C.C.1    Li, P.K.2
  • 3
    • 7044271016 scopus 로고    scopus 로고
    • Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease
    • Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004;17(5):365-70.
    • (2004) Semin Dial , vol.17 , Issue.5 , pp. 365-370
    • Snyder, R.W.1    Berns, J.S.2
  • 4
    • 3242783305 scopus 로고    scopus 로고
    • Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity
    • Yosefy C, Magen E, Kiselevich A, Priluk R, London D, Volchek L, et al. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004;44(2):215-22.
    • (2004) J. Cardiovasc. Pharmacol. , vol.44 , Issue.2 , pp. 215-222
    • Yosefy, C.1    Magen, E.2    Kiselevich, A.3    Priluk, R.4    London, D.5    Volchek, L.6
  • 5
  • 6
    • 0036116895 scopus 로고    scopus 로고
    • Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat
    • Yamashita H, Nagai Y, Takamura T, Nohara E, Kobayashi K. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism 2002;51(4):403-8.
    • (2002) Metabolism , vol.51 , Issue.4 , pp. 403-408
    • Yamashita, H.1    Nagai, Y.2    Takamura, T.3    Nohara, E.4    Kobayashi, K.5
  • 7
    • 6944250878 scopus 로고    scopus 로고
    • Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice
    • Tanimoto M, Fan Q, Gohda T, Shike T, Makita Y, Tomino Y. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metabolism 2004;53(11):1473-9.
    • (2004) Metabolism , vol.53 , Issue.11 , pp. 1473-1479
    • Tanimoto, M.1    Fan, Q.2    Gohda, T.3    Shike, T.4    Makita, Y.5    Tomino, Y.6
  • 8
    • 0034949794 scopus 로고    scopus 로고
    • Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria
    • DOI 10.1046/j.1464-5491.2001.00463.x
    • Nakamura T, Ushiyama C, Suzuki S, Shimada N, Sekizuka K, Ebihara L, et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 2001;18(4):308-13. (Pubitemid 32579361)
    • (2001) Diabetic Medicine , vol.18 , Issue.4 , pp. 308-313
    • Nakamura, T.1    Ushiyama, C.2    Suzuki, S.3    Shimada, N.4    Sekizuka, K.5    Ebihara, L.6    Koide, H.7
  • 10
    • 0033387870 scopus 로고    scopus 로고
    • Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney
    • Yang T, Michele DE, Park J, Smart AM, Lin Z, Brosius FC, et al. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 1999;277(6 Pt 2): F966-F973.
    • (1999) Am. J. Physiol. , vol.277 , Issue.2-6 PT.
    • Yang, T.1    Michele, D.E.2    Park, J.3    Smart, A.M.4    Lin, Z.5    Brosius, F.C.6
  • 11
    • 0037883037 scopus 로고    scopus 로고
    • Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients
    • Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 2003;52(8):1943-50.
    • (2003) Diabetes , vol.52 , Issue.8 , pp. 1943-1950
    • Miyazaki, Y.1    He, H.2    Mandarino, L.J.3    DeFronzo, R.A.4
  • 12
    • 0031819895 scopus 로고    scopus 로고
    • Urinary excretion rate is the best individual predictor to ESRF in non-diabetic chronic nephropathies
    • Ruggenenti P, Perna A, Mosconi L, PisoniI R, Remuzzi G. Urinary excretion rate is the best individual predictor to ESRF in non-diabetic chronic nephropathies. Kidney Int 1998;53(5):1209-16.
    • (1998) Kidney Int. , vol.53 , Issue.5 , pp. 1209-1216
    • Ruggenenti, P.1    Perna, A.2    Mosconi, L.3    PisoniI, R.4    Remuzzi, G.5
  • 13
    • 0035912555 scopus 로고    scopus 로고
    • Progression, remission, regression of chronic renal diseases
    • Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001;357(9268):1601-8.
    • (2001) Lancet , vol.357 , Issue.9268 , pp. 1601-1608
    • Ruggenenti, P.1    Schieppati, A.2    Remuzzi, G.3
  • 14
    • 0035046542 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptorgamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats
    • Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptorgamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001;59(5):1899-910.
    • (2001) Kidney Int. , vol.59 , Issue.5 , pp. 1899-1910
    • Ma, L.J.1    Marcantoni, C.2    Linton, M.F.3    Fazio, S.4    Fogo, A.B.5
  • 15
    • 0037362398 scopus 로고    scopus 로고
    • Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR) gamma activators
    • Haraguchi K, Shimura H, Onaya T. Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR) gamma activators. Clin Exp Nephrol 2003;7(1):27-32.
    • (2003) Clin. Exp. Nephrol. , vol.7 , Issue.1 , pp. 27-32
    • Haraguchi, K.1    Shimura, H.2    Onaya, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.